Zoliflodacin: A hope to treat antibiotic-resistant Neisseria gonorrhoeae
Abstract
Background: Neisseria gonorrhoeae is a gram negative diplococci which causess a sexually transmitted infection. N. gonorrhoeae is an obligate human pathogen that causes infection to the mucus-secreting epithelial cells both in male and female. In 2017, the centre of disease control and World Health Organization published the list of global priority pathogens with denting therapeutic options, including antibiotic-resistant N. gonorrhoeae. During the covid-19 pandemic, excessive use of antibiotics led to raise of drug resistance. The infection is widespread and intractable. If this happens, more people will be left with an incurable infection which may cause serious health problems.
Results: We characterized zoliflodacin thoroughly. Here is discussed the clinical trials and side effects on human health by searching different keywords like “zoliflodacin”, “covid-19”, “clinical trials” from different data sources like Pub-Med, Google-Scholar, and Science-Direct. Zoliflodacin targets antibiotic-resistant N. gonorrhoeae. Zoliflodacin is mainly known based on its therapeutic effects against N. gonorrhoeae. It acts by inhibiting bacterial type 2 topoisomerase with binding site in bacterial gyrase. Zoliflodacin is effective in treating gonococcal urogenital and rectal infection.
Conclusion: Antibiotic is the only option to treat N. gonorrhoeae. There is no vaccine available to treat gonorrhea. The new drug, zoliflodacin, specifically targets antibiotic-resistant gonorrhea and its is why researchers have studied this antibiotic from different point of views. In this study, we elaborate the discovery of zoliflodacin, its mechanism of action, the current clinical trials, and the effectiveness of zoliflodacin.
2. Hoffman O, Weber J. Review: Pathophysiology and treatment of bacterial meningitis. Ther Adv Neurol Disord 2009; 2(6):401-2.
3. Hook E, Kirkcaldy R. A brief history of evolving diagnostics and therapy for gonorrhea: lessons learned. Clin Infect.Dis 2018; 67(8):1294-9.
4. Lenz J, Dillard J. Pathogenesis of Neisseria gonorrhoeae and the host defense in ascending infections of human fallopian tube. Front Immunol 2018; 9.
5. Newman L, Rowley J, Vander Hoorn S, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One 2015; 10(12):e0143304.
6. Kirkcaldy R, Weston E, Segurado A, et al. Epidemiology of gonorrhoea: a global perspective. Sex Health 2019; 16(5):401.
7. Asokan G, Ramadhan T, Ahmed E, et al. WHO global priority pathogens list: a bibliometric analysis of medline-pubmed for knowledge mobilization to infection prevention and control practices in Bahrain. Oman Med J 2019; 34(3):184-93.
8. Jose P, Vivekanandan V, Sobhanakumari K. Gonorrhea: Historical outlook. J Skin Sex Transmitted Dis 2020; 2:110-14.
9. Zhou P, Yang X, Wang X, et al. Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 588(7836):E6-E6.
10. Crispo A, Montagnese C, Perri F, et al. COVID-19 emergency and post-emergency in italian cancer patients: how can patients be assisted?. Front Oncol 2020; 10.
11. Islam M, Sobur M, Akter M, et al. Coronavirus Disease 2019 (COVID-19) pandemic, lessons to be learned!. J Adv Vet Anim Res 2020; 7(2):260
12. Pawar A. Combating devastating COVID-19 by drug repurposing. Int J Antimicrob Agents 2020; 56(2):105984.
13. Unemo M, del Rio C, Shafer W. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr 2016; 4(3).
14. Tapsall J, Ndowa F, Lewis D, et al. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009; 7(7):821-34.
15. Kow C, Hasan S. Use of azithromycin in covid-19: a cautionary tale. Clin Drug Investig 2020; 40(10):989-990.
16. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010; 86(6):422-6.
17. Commitment to Privacy. Virginia Commonwealth University. https://lifesciences. vcu. edu/news-and-events/vcu-life-sciences/. Published 2022. Accessed January 14, 2022.
18. Unemo M, Shafer W. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future. Clin Microbiol Rev 2014; 27(3):587-613.
19. Fermer C, Kristiansen B, Sköld O, et al. Sulfonamide resistance in Neisseria meningitidis as defined by site-directed mutagenesis could have its origin in other species. J Bacteriol. 1995; 177(16):4669-75.
20. American Chemical Society. American Chemical Society. https://www. acs. org/. Published 2022. Accessed January 14, 2022.
21. National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 76685216, Zoliflodacin. Retrieved March 20, 2022 from https://pubchem. ncbi. nlm. nih. gov/compound/Zoliflodacin.
22. Bradford P, Miller A, O’Donnell J, et al. Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect Dis. 2020; 6(6):1332-45.
23. Basarab G, Kern G, McNulty J, et al. Erratum: Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci Rep 2015; 5(1).
24. Unemo M, Ringlander J, Wiggins C, et al. High in vitro susceptibility to the novel spiropyrimidinetrione etx0914 (azd0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 european countries from 2012 to 2014. Antimicrob Agents Chemother 2015; 59(9):5220-5.
25. Jacobsson S, Golparian D, Oxelbark J, et al. Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model. Front Pharmacol 2021;12.
26. Taylor S, Marrazzo J, Batteiger B, et al. Single-dose zoliflodacin (etx0914) for treatment of urogenital gonorrhea. New England Journal of Medicine 2018; 379(19):1835-45.
27. Foerster S, Drusano G, Golparian D, et al. In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae. J Antimicrobial Chemother 2019; 74(12):3521-9.
28. VanScoy B, Scangarella-Oman N, Fikes S, et al. Relationship between gepotidacin exposure and prevention of on-therapy resistance amplification in a Neisseria gonorrhoeae hollow-fiber in vitro infection model. Antimicrob Agents Chemother. 2020; 64(10).
29. GARDP and Entasis Therapeutics initiate global phase 3 trial of zoliflodacin, a first-in-class oral antibiotic for the treatment of gonorrhoea- GARDP. GARDP. https://gardp. org/news-resources/gardp-and-entasis-therapeutics-initiate-global-phase-3-trial-of-zoliflodacin-a-first-in-class-oral-antibiotic-for-the-treatment-of-gonorrhoea/. Published 2022. Accessed January 14, 2022.
30. U. S. National library of medicine available at: https://www. clinicaltrials. gov/show/NCT03613649.
31. U. S. National library of medicine available at: https://www. clinicaltrials. gov/show/NCT03718806.
32. U. S. National library of medicine available at: https://www. clinicaltrials. gov/show/NCT03404167.
33. U. S. National library of medicine available at: https://www. clinicaltrials. gov/show/NCT02257918.
34. U. S. National library of medicine available at: https://www. clinicaltrials. gov/show/NCT03959527.
| Files | ||
| Issue | Vol 11 No 1-2 (2023) | |
| Section | Review Articles | |
| DOI | https://doi.org/10.18502/jmb.v11i1-2.14372 | |
| Keywords | ||
| Neisseria gonorrheae Zoliflodacin Covid-19 Antibiotic-resistance Treatment. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
